KiraGen was selected as a Boston Regional Finalist in the Alumni Track of the 2025 Harvard Business School New Venture Competition.
The regional round gave KiraGen an opportunity to present its multiplex-engineered cell-therapy strategy and lead glioblastoma program to judges and investors.
Regional winners advanced to the global finals, where the top award was $75,000.